Explains bill will restrict DUR operations. Notes
that DUR will not be able to review new drugs prior to market approval.

162

Jim Gardner

Pharmaceutical Research and Manufacturers of America
(PhRMA). Explains key issue relates to priority line for specific treatments
relating to the DUR Board recommendations. Explains treat-ability of
conditions and new conditions that fall below the priority line are preemptively
removed from consideration.

200

Rep. Anderson

Questions drug safety.

203

Gardner

Explains drug is FDA approved.

216

Rep. Tomei

Inquires on marketing of drugs later proven
ineffective.

219

Gardner

Comments on role of DUR to monitor drugs. Notes drugs
were stricken before FDA approval.

229

Rep. Tomei

Inquires on ability of DUR Board to change decision.

234

Gardner

Assesses situation as an effort to establish a
policy to preemptively determine drug coverage.

242

Rep. Tomei

Inquires on impact on patient of prescribing drug
then removing it from Medicaid coverage.

248

Gardner

Explains the diagnostic codes for prescriptions used
to edit out specific drugs for treating conditions that fall below the line.